SCHEMBL615156

SCHEMBL615156

COC(=O)c1nc(C2=CCNCC2)cnc1N

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ATR Q13535 6/20 0.42
TYRO3 Q06418 3/20 0.37
PRKDC P78527 2/20 0.36
CCNT1 O60563 2/20 0.36
CDK9 P50750 2/20 0.36
TBK1 Q9UHD2 1/20 0.35
WNT3A P56704 1/20 0.35
SCN9A Q15858 1/20 0.35
ALK Q9UM73 2/20 0.35
QDPR P09417 1/20 0.34
PIK3CA P42336 1/20 0.34
MTOR P42345 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63723 0.78 WNT3A (0.39) CCNT1CDK9WNT3ASCN9AQDPR
SCHEMBL31705725 0.77 HRH3 (0.38) CCNT1CDK9WNT3ASCN9AQDPR
SCHEMBL22047337 0.74 SPR (0.47) CCNT1CDK9WNT3AQDPR
SCHEMBL2465346 0.73 GSK3B (0.37) ATRTYRO3PRKDC
SCHEMBL617489 0.72 GSK3B (0.44) ATRPRKDC
SCHEMBL31706419 0.72 QDPR (0.36) CCNT1CDK9WNT3ASCN9AQDPR
SCHEMBL7934174 0.72 SCN9A (0.40) CCNT1CDK9SCN9AQDPR
SCHEMBL31704506 0.72 QDPR (0.36) CCNT1CDK9WNT3ASCN9AQDPR
SCHEMBL12537881 0.71 L3MBTL1 (0.45) CCNT1CDK9
SCHEMBL614867 0.70 ATR (0.47) ATRTYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140113005-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-04-24 US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
EP-2370424-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2011-10-05 EP disclosed
WO-2010054398-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-14 WO disclosed
WO-2010054398-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140113005-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 ATR 1/4885TYRO3 816/4885PRKDC 6/4885
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 ATR 1/4885TYRO3 816/4885PRKDC 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.